chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Odd swollen lymph node above collarbone on left side of neck noticed on day 9 after shot (same side as injection) & headaches in the morning 3 or 4 of last 10 days.; Odd swollen lymph node above collarbone on left side of neck noticed on day 9 after shot (same side as injection) & headaches in the morning 3 or 4 of last 10 days.; This is a spontaneous report from a non-contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 01Apr2021 at 15:45 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included pituitary disorder (reported as Pituitary gland condition). The patient had no known allergies to medications, food, or other products. Concomitant medications taken within two weeks of vaccination. included ibuprofen (MANUFACTURER UNKNOWN), famotidine (MANUFACTURER UNKNOWN), both for unknown indication from unknown date and cortisone (MANUFACTURER UNKNOWN) (reported as cortisone shot) from unknown date for injury. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced odd swollen lymph node above collarbone on left side of neck noticed on 09Apr2021, day nine after shot (same side as injection) and headaches in the morning 3 or 4 of last 10 days from an unknown date in Apr2021. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events odd swollen lymph node above collarbone on left side of neck noticed on day 9 after shot (same side as injection) and headaches in the morning 3 or 4 of last 10 days was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
He had blisters on the left side of his back. He went to urgent care and he was diagnosed with Shingles. He took Motrin to treat it. It was painful for three weeks, but then it cleared up in five to six weeks.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 74-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 24Sep2022 as dose 5 (booster), single (Lot number: G23277) at the age of 74 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. Past drug history included: Tetracycline, reaction(s): "Known allergies:Tetracycline"; Composine, reaction(s): "Known allergies: Composine". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19. The patient received Paxlovid as treatment medication from 04Dec2022 to 10Dec2022 for Covid-19.
Vaccines were exposed to 31.5f for 2 hours 45 minutes and menquadfi were administered to patients after excursion with no reported adverse event; Initial information was received on 04-Aug-2023 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 11 years old female patient who experienced vaccines were exposed to 31.5f for 2 hours 45 minutes and menquadfi were administered to patients after excursion with no reported adverse event while receiving vaccine meningococcal a-c-y-w135 (t conj) vaccine [Menquadfi].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included diphtheria vaccine toxoid, pertussis vaccine acellular 5-component, tetanus vaccine toxoid (Adacel) for Prophylactic vaccination (Immunisation).  On an unknown date, the patient received a dose of suspect meningococcal a-c-y-w135 (t conj) vaccine Solution for injection at dose of 0.5 ml (strength, lot number, expiration date: Unknown) via intramuscular route in unknown administration site for Immunization (immunization) was exposed to 31.5 f for 2 hours 45 minutes and menquadfi were administered to patients after excursion with no reported adverse event (poor quality product administered) (latency: same day). Information on the batch number was requested.  No lab data reported.  Action taken: not applicable.  At time of reporting, the outcome was Unknown for the event vaccines were exposed to 31.5f for 2 hours 45 minutes and menquadfi were administered to patients after excursion with no reported adverse event.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Soreness in the site of injection; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (Soreness in the site of injection) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011M20A, 048A21A, 014F21A and 056A22A) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy (Codeine) and Drug allergy (Vicodin).   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 06-May-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Feb-2021, the patient experienced VACCINATION SITE PAIN (Soreness in the site of injection). On 06-May-2022, VACCINATION SITE PAIN (Soreness in the site of injection) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient was not under any concomitant or regular medication.  Patient did not have any medical history relating to mentioned AE and both Acute and Chronic illnesses at the time of vaccination. Patient did not have any COVID positive test or diagnosis.  Patient only felt soreness in the site of injection during 1 day after each vaccine i.e. on 12 Feb 2021, 12 Mar 2021, 17 Nov 2021 and 06 May 2022.  No treatment medication was provided.   This case was linked to MOD-2022-676047 (Patient Link).
RED SPOTS ON BOTH THIGHS; This spontaneous report received from a patient concerned a 63 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included morphine allergy, betadine allergy, abstains from alcohol, non-smoker, and latex allergy, and other pre-existing medical conditions included the patient was not a drug abuse or illicit drug user. The patient received covid-19 vaccine  (suspension for injection, route of admin not reported, and batch number: 206A21A expiry: 23-JUN-2021) dose was not reported, administered on 04-MAY-2021 13:00 for prophylactic vaccination. No concomitant medications were reported. On 14-MAY-2021, the subject experienced red spots on both thighs. The action taken with covid-19 vaccine  was not applicable. The patient recovered from red spots on both thighs on 14-MAY-2021. This report was non-serious.
Pain at injection site lasting 48 hours, fatigue, headache, muscle pain, chills, nausea
319 patients received dose from vials beyond 30-day use by date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (319 patients received dose from vials beyond 30-day use by date) in a 20-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Aug-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (319 patients received dose from vials beyond 30-day use by date). On 19-Aug-2021, EXPIRED PRODUCT ADMINISTERED (319 patients received dose from vials beyond 30-day use by date) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported. No treatment medications reported. No adverse event reported.  The date of refrigeration of the dose used by the patient was on 07-May-2021 as per the report.   This case was linked to MOD-2021-365129 (Patient Link).
YELLOW FEVER - RED CIRCLE WITH BRUISING IN CENTER (WITH LOSS OF RED COLOR) ONLY IN CENTER OF INJECTION SITE - OCCURED AT 6 DAY AFTER INJ.  TDAP - EXTREME SWELLING (EGG SIZE), ICHING, REDNESS DIAMETER SIZE OF GRAPEFRUIT WITH FINGER LOOKING RED GOING DOWN ARM - NEXT AND SHOULDER SORENESS ON INJECTION ARM SIDE ONLY - LOW GRADE FEVER, ACHES, PAIN IN ARM AND SHOULD, HEADACHE, AND EXTREME FATIGUE EXPERIENCE DAY AFTER SHOT - SWELLING CONTINUES EACH DAY.  NOW AT DAY 4.
Pre-syncope after exercise. found to have orthostatic hypotension and dysautonomia, diagnosed in the weeks following the second vaccination. Persistent light headedness, urinary symptoms, weight loss. Possible pure autonomic failure. Evaluation ongoing.
2 days after receiving Hepatitis A and DTap the pt presents with redness, swelling, localized fever, and contact dermatitis.
Vomiting, nausea, diarrhea approx. 13 hours after vaccine was received. Chills and heat flashes also. Dizziness, too.
SORE SPOT AT THE VACCINATION ABOUT THE SIZE OF A QUARTER; This spontaneous report received from a patient via a company representative via social media (Johnson & Johnson) concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient previously received covid-19 vaccine ad26.cov2.s (Dose number in series 1) (suspension for injection, route of admin was not reported, batch number: Unknown, expiry: Unknown) dose was not reported, 1 total, administered on an unspecified date for covid-19 prophylaxis.  The patient experienced sore spot at the vaccination about the size of a quarter with outcome recovered (duration 2 weeks) following vaccination with covid-19 vaccine ad26.cov2.s (Dose number in series 1). The patient received booster dose of covid-19 vaccine ad26.cov2.s (Dose number in series 2) (suspension for injection, route of admin was not reported, batch number: Unknown, expiry: Unknown) dose was not reported, 1 total, administered on an unspecified date (four months later after initial vaccine) for covid-19 prophylaxis. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date, the patient experienced sore spot at the vaccination about the size of a quarter (duration 2 weeks) (Dose number in series 2). The patient had no other noticeable reactions. The reporter stated that "I took the vaccination and 4 months later I took their booster, which was the same as the original vaccine. Both times I had a sore spot at the vaccination, about the size of a quarter for almost two weeks, but no other noticeable reactions". The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from sore spot at the vaccination about the size of a quarter. This report was non-serious. This case, involving the same patient is linked to 20221234743.
This is a spontaneous report from a contactable consumer (patient).  A 70-years-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTEC COVID-19 VACCINE, Solution for injection, Lot Number: EN5318) via an unspecified route of administration on 03Feb2021 at 11:00 (at the age of 70-years-old) as a single dose for COVID-19 immunization. Medical history not reported. Concomitant medication included antihistamine. patient had allergies to sulfa and latex. Patient did not receive other vaccine in four weeks of vaccination. Patient was not diagnosed with COVID-19, prior vaccination. Patient was tested COVID post vaccination. On 06Feb2021 (on the 3rd day) at 16:00, patient experienced that her throat felt like it was closing and could not swallow. The swallow reflex would not work. This went on for around an hour. No treatment was received. Patient wants to know if this happens again with the 2nd dose or should not take the 2nd dose. Lab test covid test: unknown. The outcome of all events was recovered. Follow-up attempts completed. No further information expected.
I had a cough and a headache as well as sneezing. I also lost all sense of taste and smell, but it has come back. I have less than half of the sense of smell than I had before. I completed a COVID-19 test on March 3rd, 2023. I tested negative again after a week. I treated my symptoms with Tylenol and check for fever which I didn't have. I took Zinc and Vitamin C. I am completely recovered except for the sense of smell.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 15Sep2022 as dose 5 (booster), single (Lot number: Gj53uz) at the age of 54 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Other medication in 2weeks product: Anti depressant" (unspecified if ongoing), notes: Other medication in 2weeks product: Anti depressant. Concomitant medication(s) included: DULOXETINE; ADDERALL; TAMSULOSIN. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Nov2022, outcome "recovered" (Dec2022) and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: The patient had no Known allergies and Other medical history. The patient received other medications included Anti depressant, Duloxetine, Adderal and Tamsulosin within 2 weeks of vaccination. The patient received Paxlovid as treatment of COVID-19 from 30Nov2022 to 04Dec2022.
Patient was nauseous, and short of breath. Patient had several episodes of vomiting, He stated he had a "tickle" in his throat and felt his airway was obstructed. Pharmacist. administered diphenhydramine 25mg po x2.
Received vaccines on 1/3/03 at 10:30 and at 15:00 began with red thighs, swollen at site, fever of 101.4F and crying uncontrollably. Fever and crying lasted until 1/6/03.
Patient was given the Moderna vaccine instead of the Pfizer vaccine.  Pt is 12 years old.  There were no adverse reactions stated by the mother.  Patient came in with her mother for the second vaccine.  That is when I discovered that she had been given the wrong vaccine for her first shot.  Dr. was called and recommended that the patient stay with the same vaccine series if the mother was ok with it.  I spoke with the mother and told her Dr. recommendation.  Mom was not upset.  She knew the daughter had the Moderna shot the first time and wanted the daughter to receive the second Moderna vaccination.  Mother stated that she did not notice any adverse reactions.
One hour after receiving started with profuse sweating, irregular heart beat, continued next day, numbness & tingling of extremities, disorientation, weak & tired. Allergic to vaccine component, monosodium glutamate. This should be listed on patient info. sheet. Contains MSG!
Oxygen levels in the 80s for 6 hours the first 10 after injection with the 2nd dose; Heart rate between 120-130; A fever of 102; This spontaneous case was reported by a consumer and describes the occurrence of OXYGEN SATURATION DECREASED (Oxygen levels in the 80s for 6 hours the first 10 after injection with the 2nd dose), TACHYCARDIA (Heart rate between 120-130) and PYREXIA (A fever of 102) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced OXYGEN SATURATION DECREASED (Oxygen levels in the 80s for 6 hours the first 10 after injection with the 2nd dose), TACHYCARDIA (Heart rate between 120-130) and PYREXIA (A fever of 102). At the time of the report, OXYGEN SATURATION DECREASED (Oxygen levels in the 80s for 6 hours the first 10 after injection with the 2nd dose), TACHYCARDIA (Heart rate between 120-130) and PYREXIA (A fever of 102) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 102 (High) A fever of 102. On an unknown date, Heart rate: 120-130 (High) 120-130. On an unknown date, Oxygen saturation: low (Low) Oxygen levels in 80s for 6 hours the first 10 after injection with the 2nd dose).         No concomitant medication information was provided.  No treatment medication were provided.   This case was linked to MOD-2021-311256 (Patient Link).; Sender's Comments: Based on current available information and the temporal associations between product and the start date of the events a causal relationship cannot be excluded.
pt recv vax 29JUL96 & 4AUG96 pt devel swelling, soft tissue & tenderness @ base of neck in supraclavicular area;also exp sl soreness in throat;pt swelling @ base of neck persisted;
This spontaneous report was received from a consumer and refers to her nephew, an approximately 16 year old male patient. Concurrent conditions, medical history, historical or concomitant drugs were not reported. On an unspecified date approximately in 2017 (reported as "last year"), the patient was vaccinated with the first dose of GARDASIL 9 Injection, for prophylaxis (strength, dose, route, anatomical location, lot # and expiration date were not reported). After that, on an unknown date, the patient experienced flu-like symptoms. Then, also on an unknown date, the patient received the second dose of GARDASIL 9 Injection, for prophylaxis (strength, dose, route, anatomical location, lot # and expiration date were not reported). After that dose, he experienced fever of 103 F. The patient sought medical attention. According to the reporter, the patient and his parents decided to refuse the administration of the third dose of GARDASIL 9. The outcome of the events was reported as recovered on unknown dates. The reporter did not provide the causal relationship between the events and vaccination with GARDASIL 9. This is one of several reports coming from the same source. Sender's Comments: US-009507513-1807USA011111.
Information has been received from a physician concerning a patient who on an unspecified date was vaccinated with a 0.5mL dose of varicella virus vaccine live. The physician reported that 10 days after receiving vaccination with varicella virus vaccine live the pt had a mild breakthrough of chickenpox. Additional information from the physician reported that the pt developed a rash 15 days after the vaccination varicella virus vaccine live and his parents took him to an emergency dept. where the parents were told the pt had chickenpox. The pt was not admitted. The physician reported the pt was then seen by him three days after the ER visit and he indicated that he disagreed with the diagnosis of chickenpox and he sent the child to a dermatologist. The dermatologist diagnosed the pt with eczema. The physician does not think the eczema had anything to do with the vaccination. It was unknown whether treatment was required for the adverse event. The adverse event abated, and the pt fully recovered.  No additional information was provided. There was no product quality complaint reported. Unspecified medical attention was sought. No additional information is expected.
"Cut body" (Flu-like symptoms); fever; This is a spontaneous report from a contactable healthcare professional (patient himself). A 37-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), via an unspecified route of administration on 11Mar2021 at 05:00 (Batch/Lot number was not reported) (at the age of 37-years-old) as unknown, single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. Patient was not diagnosed with COVID-19 prior to vaccination. Patient did not received any vaccines within 4 weeks prior to Covid vaccine. On 11Mar2021 at 12:15, patient experienced "cut body" (flu-like symptoms) and fever. Since the vaccination, the patient had not been tested for COVID-19. Outcome of events was unknown.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
3/10/08, patient was given her 2nd GARDASIL vaccine, initially tolerated well.  She was standing at the checkout area approximately 10 minutes after injection and passed out hitting her head on counter.  She had a concussion, was sent to ER.  While in ER CT scan which revealed 2 hair line fractures of occipital bone.
pt recvd vax;exp fever greater than 101,general malaise,sore throat & devel a chicken pox rash;
Pateint returned for his 2nd dose of Moderna when it was realized he was under the age of 18. Patient was advised to consult with his parent and primary care physician for recommendations for further vaccination. Patient has not recieved the 2nd dose of Moderna awating advice from primary care physician.
Sore throat; This is spontaneous report from a contactable consumer (patient). This 25-year-old non-pregnant female patient received the first dose of (PFIZER-BIONTECH COVID-19 MRNA VACCINE;) via an unspecified route of administration in the left arm on 23Apr2021 at 13:45 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included bipolar disorder, anorexia, anxiety, osteopenia, and sulfa allergy, all from unknown dates and unknown if ongoing. Prior to vaccination the patient was not diagnosed with COVID-19 and had not received any other vaccines in the 4 weeks prior to the COVID vaccine. Concomitant medications included oxcarbazepine from an unknown date for an unknown indication. The patient reported she experienced a sore throat that started the night she got the vaccine and had persisted for almost a week on 23Apr2021 at 22:30; further reporting she experienced no other symptoms. No treatment was received for the event. The clinical outcome of sore throat was not recovered. It was also reported that since vaccination the patient had not been tested for COVID-19.  No follow-up attempts are needed. No further information is expected.